|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Bioinformatics analyses conducted on a Caucasian-based cDNA microarray databank showed Ar to be positively associated with GCa prognosis for multiple clinical modalities, including surgery, 5-Fluorouracil (5-FU) for adjuvant chemotherapy, or HER2 positivity.
|
31557413 |
2019 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Patterns of somatic mutation in human cancer genomes.
|
17344846 |
2007 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We recommend the number of tumor containing fragments be described in the HER2 IHC pathology reports for clinical reference in endoscopic biopsy specimens of GC.
|
28549444 |
2017 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
|
30442682 |
2019 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PPP1R1B-STARD3-TCAP-PNMT-PERLD1-ERBB2-MGC14832-GRB7 locus at human chromosome 17q12 is frequently amplified in human gastric cancer and breast cancer.
|
15010812 |
2004 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Coamplified and overexpressed genes at ERBB2 locus in gastric cancer.
|
14991576 |
2004 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association analysis of ERBB2 amplicon genetic polymorphisms and STARD3 expression with risk of gastric cancer in the Chinese population.
|
24291029 |
2014 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The SNPs rs2643194, rs2934971, and rs1058808 of the ERBB2 gene were associated with increased risk for GC.
|
31116314 |
2019 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Lung cancer: intragenic ERBB2 kinase mutations in tumours.
|
15457249 |
2004 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
EBV-encoded RNA-positive cases were significantly associated with GC-MLI (P<.001), lower age (P=.016), diffuse/mixed type of histology (P=.011), and lower HER2 expression (P=.032).
|
27260946 |
2016 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ERBB2 kinase domain mutation in a gastric cancer metastasis.
|
16309427 |
2005 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Prognostic implications of HER2 heterogeneity in gastric cancer.
|
29507688 |
2018 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma.
|
12579211 |
2002 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study aimed to elucidate the relationship between NPM and Her-2 in gastric cancer cell lines and clinical samples, and further investigated their role in the resistance of gastric cancer to oxaliplatin.
|
28454407 |
2017 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
|
21505336 |
2011 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier.
|
21058730 |
2010 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data suggest that immuno-liposome mediated delivery of drugs is a promising new therapeutic option for patients with advanced gastric cancer that overexpress Her2/neu.
|
21109923 |
2011 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 detection in mixed gastric carcinoma displays high heterogeneity.
|
25914479 |
2015 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the clinical significance of multi-targeting tyrosine kinase inhibitors (TKIs) in HER2-positive gastric cancer remains unclear.
|
31704817 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
c-erbB-2 oncogene has been reported to be frequently amplified in differentiated, tubular type of gastric cancer.
|
2575609 |
1989 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Gastric cancer (GC) has also been slow to benefit from biomarker discovery and development and the successful utilisation of targeted therapies, with the exception of trastuzumab in HER2 positive cancers.
|
30597479 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The anti-ErbB2 antibody trastuzumab has currently been approved for ErbB2-positive gastric cancer.
|
24668364 |
2014 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Intratumoral heterogeneity of HER2 expression in the metastatic foci of HER2-positive advanced gastric cancer remains unclear.
|
25828363 |
2015 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Consensus guidelines have standardized the testing of HER2 status in gastric cancer.
|
23021388 |
2013 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Patients with chemotherapy-naive HER2-positive advanced gastric cancer were eligible.
|
26857702 |
2016 |